Scott April, Salgia Ravi
University of Chicago, Department of Medicine, Section of Hematology/Oncology, and University of Chicago Cancer Research Center, 5841 S Maryland Avenue, Chicago, IL 60637, USA.
Biomark Med. 2008 Dec 1;2(6):577-586. doi: 10.2217/17520363.2.6.577.
Lung cancer remains a significant cause of mortality worldwide. While advances in therapy continue to be made, the overall prognosis for patients diagnosed with lung cancer remains poor. Historically, markers such as age, performance status and disease stage have been used to risk-stratify patients and guide therapeutic decisions. These parameters provide some useful information, but more sensitive markers are clearly needed. Molecular and genetic studies have identified several such markers, which appear to play critical roles in carcinogenesis and affect patient outcomes. This article reviews a number of biomarkers that have been identified in lung cancer, and their prognostic and predictive roles.
肺癌仍然是全球范围内导致死亡的一个重要原因。尽管治疗方面不断取得进展，但被诊断为肺癌的患者总体预后仍然很差。从历史上看，诸如年龄、身体状况和疾病分期等指标一直被用于对患者进行风险分层并指导治疗决策。这些参数提供了一些有用信息，但显然需要更敏感的指标。分子和遗传学研究已经确定了几种这样的指标，它们似乎在癌症发生过程中发挥关键作用并影响患者的预后。本文综述了在肺癌中已确定的一些生物标志物及其预后和预测作用。
